<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00042887</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-30004</org_study_id>
    <secondary_id>EORTC-30004</secondary_id>
    <nct_id>NCT00042887</nct_id>
  </id_info>
  <brief_title>Chemotherapy With or Without Surgery in Treating Patients With Bladder Cancer</brief_title>
  <official_title>Chemoresection With 4 Weekly Intravesical Instillations Of Mitomycin C Versus Transurethral Resection (TUR) Followed By One Single Immediate Instillation Of Mitomycin C In Single, Small, Papillary Stage Ta, T1 Bladder Tumors: A Prospective Randomized Phase III Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Infusing chemotherapy drugs directly into the bladder may kill more&#xD;
      cancer cells. It is not yet known if surgery followed by chemotherapy is more effective than&#xD;
      chemotherapy alone in treating bladder cancer.&#xD;
&#xD;
      PURPOSE: Randomized phase III trial to compare the effectiveness of chemotherapy alone with&#xD;
      that of transurethral resection followed by chemotherapy in treating patients who have&#xD;
      bladder cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the efficacy of chemoresection with 4 weekly intravesical instillations of&#xD;
           mitomycin vs transurethral resection followed by 1 instillation of mitomycin in patients&#xD;
           with low-risk superficial transitional cell carcinoma of the bladder.&#xD;
&#xD;
        -  Compare the disease-free survival of patients treated with these regimens.&#xD;
&#xD;
        -  Determine the response rate at 6 weeks in patients treated with chemoresection.&#xD;
&#xD;
        -  Determine the percent of patients with tumor at 6 weeks treated with transurethral&#xD;
           resection.&#xD;
&#xD;
        -  Compare the quality of life of patients treated with these regimens.&#xD;
&#xD;
        -  Compare the side effects of these regimens in these patients.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to&#xD;
      disease status (primary vs recurrent) and participating center. Patients are randomized to 1&#xD;
      of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients undergo chemoresection with intravesical instillation of mitomycin once&#xD;
           weekly for 4 weeks.&#xD;
&#xD;
        -  Arm II: Patients undergo transurethral resection followed within 1-6 hours by&#xD;
           intravesical instillation of mitomycin.&#xD;
&#xD;
      Quality of life is assessed at baseline, at week 1 (arm II only), at week 5 (arm I only), and&#xD;
      then at week 6.&#xD;
&#xD;
      Patients are followed at weeks 6 and 19, every 6 months for 3 years, and then annually for 2&#xD;
      years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 1,000 patients (500 per treatment arm) will be accrued for this&#xD;
      study within 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    low accrual&#xD;
  </why_stopped>
  <start_date>May 2002</start_date>
  <primary_completion_date type="Actual">May 2004</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">58</enrollment>
  <condition>Bladder Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mitomycin C</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Cytologically confirmed solitary primary or recurrent papillary transitional cell&#xD;
             carcinoma of the bladder&#xD;
&#xD;
               -  Ta or T1&#xD;
&#xD;
          -  Tumor no greater than 2 cm in diameter&#xD;
&#xD;
          -  Negative urine cytology&#xD;
&#xD;
          -  No suspicious lesions in bladder requiring biopsy&#xD;
&#xD;
          -  No tumors in the prostatic urethra or upper urinary tract&#xD;
&#xD;
          -  No prior history of T1 G3 tumors, muscle invasive tumors (T2 or greater), or carcinoma&#xD;
             in situ&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  80 and under&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  WHO 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No active intractable or uncontrollable bladder infection&#xD;
&#xD;
          -  No urethral strictures that would preclude endoscopic procedures or repeated&#xD;
             catheterization&#xD;
&#xD;
          -  No prior or concurrent congenital or acquired immune deficiency syndrome&#xD;
&#xD;
          -  No other prior or concurrent malignancy except cured basal cell skin cancer or&#xD;
             intraepithelial cancer of the cervix&#xD;
&#xD;
          -  No prior or concurrent leukemia or Hodgkin's disease&#xD;
&#xD;
          -  No concurrent disease for which general anesthesia is contraindicated&#xD;
&#xD;
          -  No psychological, familial, sociological, or geographical condition that would&#xD;
             preclude study compliance&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  More than 12 months since prior BCG vaccine&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  At least 1 year since prior mitomycin&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No prior pelvic radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  No prior organ transplant&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  At least 3 months since prior intravesical treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Willem Oosterlinck, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Universitair Ziekenhuis Gent</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Academisch Ziekenhuis der Vrije Universiteit Brussel</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Ghent</city>
        <zip>B-9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virga Jesse Hospital</name>
      <address>
        <city>Hasselt</city>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.Z. Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>B-3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita Di Palermo</name>
      <address>
        <city>Palermo</city>
        <zip>90141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S.S. Annunziata</name>
      <address>
        <city>Savigliano</city>
        <zip>12038</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onze Lieve Vrouwe Gasthuis</name>
      <address>
        <city>Amsterdam</city>
        <zip>1091 HA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jeroen Bosch Ziekenhuis</name>
      <address>
        <city>NL'S Hertogenbosch</city>
        <zip>NL-5211</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daniel Den Hoed Cancer Center at Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3008 AE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comenius University School of Medicine</name>
      <address>
        <city>Martin</city>
        <zip>03659</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dokuz Eylul University School of Medicine</name>
      <address>
        <city>Izmir</city>
        <zip>35340</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Slovakia</country>
    <country>Turkey</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <study_first_submitted>August 5, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>September 20, 2012</last_update_submitted>
  <last_update_submitted_qc>September 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage 0 bladder cancer</keyword>
  <keyword>stage I bladder cancer</keyword>
  <keyword>recurrent bladder cancer</keyword>
  <keyword>transitional cell carcinoma of the bladder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

